Stock listing
Prelude Therapeutics Incorporated
Selected listing: PRLD · NASDAQ · USD · US
Prelude Therapeutics Incorporated (NASDAQ:PRLD), Health Technology. Latest release Sep 11, 2026: Prelude Therapeutics to Participate in the H.C. Wainwright…
- Ticker
- NASDAQ:PRLD
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
About Prelude Therapeutics Incorporated
The company focuses on developing innovative therapies for cancer treatment. Prelude Therapeutics is committed to advancing its pipeline of drug candidates to address unmet medical needs in oncology.
Latest news from Prelude Therapeutics Incorporated
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 11, 2026
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
September 10, 2026
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 12, 2026
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
April 20, 2026
Events
Replays
Prelude Therapeutics Incorporated (PRLD) Q3 2025 Earnings Call
Wed, Nov 12, 2025 · 08:00 AM ET
Watch
Research Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated company profile
View the public company page for Prelude Therapeutics Incorporated on 6ix.
Prelude Therapeutics Incorporated news
Read company news and market updates connected to Prelude Therapeutics Incorporated.
Prelude Therapeutics Incorporated investor events
Find investor webinars, events, and replay context for Prelude Therapeutics Incorporated.